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Time of onset of coronary artery  
disease in diabetic patients depends  
on genetic polymorphism in region 9p21 
but not in 1p25
ABSTRACT
Introduction. Type 2 diabetes (T2DM) is an important 
risk factor for development of coronary artery disease 
(CAD) and its complications. Recent genetic studies 
revealed possible association between those two 
conditions on the genome level. In our study we ana-
lysed whether polymorphisms in loci 1q25 and 9p21, 
previously characterized as risk factors of CVD, have 
an influence on early-onset CAD in T2DM patients.
Materials and methods. Our case-control study included 
338 patients suffering from T2DM and CAD. For the 
study purpose the cohort was divided into two groups 
based on the age of CAD onset: case group with early-
onset CAD (< 55 for males and < 65 years for females, 
n = 180) and control group (≥ 55 and ≥ 65 years respec-
tively, n = 158). Epidemiological data was taken from 
medical history and retrospective questionnaire; blood 
samples were collected. The rs2383206, rs1333049 and 
rs10911021 were genotyped using method of fluores-
cently labelled allele specific oligonucleotides.
Results. Statistical analysis did not reveal any significant 
differences between two groups in the mean duration of 
diabetes, metabolic parameters (weight, waist circum - 
ference, frequency of obesity according to BMI, mean 
blood pressure or lipids levels) and smoking history. 
There were statistical differences between groups in fam-
ily incidence of CAD (70.0% patients in cases vs. 45.6% 
in controls; p < 0.005), hypertension (77.1% vs. 47.8%; 
p < 0.005) and obesity (61.2% vs. 49.0%; p < 0.05). 
Genetic analysis revealed that frequency of the G allele 
of rs2383206 in 9p21 region was significantly higher in 
cases than in controls (62.4% vs 44.0% p < 0.00001). 
Homozygotes GG were 39.4% of cases and 18.8% 
in controls (p = 0.0001). The OR for increased risk 
of early CAD in GG homozygotes was 2.81, 95% CI: 
2.39–3.24, after adjustment for conventional risk 
factors it was reduced to 2.58. There was statistically 
significantly higher frequency of GG homozygotes 
among patients with poor glycaemic control (HbA1c 
≥ 7%; 41.3% vs. 15.9; p = 0.0011) and non-obese sub-
jects (BMI < 30 kg/m2; 39.7% vs. 18.2%, p = 0.0002). 
Similar association between genotype and risk of early 
CAD was found for another polymorphism rs1333049 in 
9p21 region. Frequency of allele C was significantly high-
er in cases than in controls (56.3% vs 43.4, p = 0.0036) 
and homozygotes CC were 31.6% in cases and 17.4% 
in controls (p = 0.0083). OR for this association was 
2.2 (95% CI: 1.83–2.56); after adjustments 1.96. We 
didn’t find any association between genotypes distri-
bution of rs10911021 and early onset of CAD.
Conclusions. Our findings clearly suggest that polymor-
phisms in 9p21 region have an influence on development 
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of early-onset CAD in T2DM, especially in non-obese 
patients and subjects with poor glycaemic control. 
 (Clin Diabet 2016; 5, 1: 7–14)
Key words: T2DM, HbA1c, CAD, genetics, 9p21,  
1q25, polimorphism
Introduction
Cardiovascular disease (CVD) is an important 
medical and economical problem in highly urbanized 
countries. According to medical statistics, coronary ar-
tery disease (CAD), stroke and other arterial thrombotic 
events are major reasons for disability and mortality 
among middle-age and elder individuals [1, 2]. Since 
medical consequences of stroke or myocardial infarc-
tion are often irreversible and lead to long-lasting 
burden for health-care system, prophylaxis and early 
medical intervention play a key role in management 
of patients with CVD. Therefore, identification of risk 
factors and optimal selection of therapeutic options are 
crucial for effective CVD prevention. Some risk factors 
of CVD, i.e. hypertriglyceridaemia, obesity, smoking, 
excessive alcohol use, are strongly related to patient’s 
lifestyle, and are best modified by lifestyle changes. Some 
others like age, gender or genetic background cannot be 
modified, but nevertheless they are taken into account 
in a total CVD risk assessment in a given subject.
In the last two decades genetic studies identified 
number of polymorphisms and mutations contribut-
ing to the risk and outcome of cardio-vascular events. 
The role of some genes has been well-characterized 
in pathogenesis of stroke and myocardial infarction. 
However there are still many genome loci already de-
fined as important for development of CVD but with 
unknown gene structure and function. These „hot 
places” were identified mainly by multiple SNP analysis 
(single nucleotide polymorphism) in whole genome 
studies searching for association between genetic vari-
ants and susceptibility to common diseases. Only for 
coronary artery disease more than 50 important genetic 
loci were found using genome-wide association studies 
(GWAS) [4–7]. However, so far the biological role and 
possible mechanism of action has been established for 
less than 50% of identified polymorphisms. Majority 
of genes important for development of CVD are as-
sociated mainly with lipids metabolism (LPA, SORT1, 
LDLR, APOE) or blood pressure stabilization (ACE, 
AT1R, SH2B3) [13–15]. Other possible gene candidates, 
identified in multiple genome regions like 1q41, 2q36, 
6p24, 9p21, 10q11.21 or 15q25 contribute probably 
in regulation of cell cycle, tissue growth, homeostasis, 
fibrinolysis and inflammatory response. Their direct 
mechanism of action in atherosclerosis is not clear. 
Further studies of molecular pathways associated with 
genetic predisposition to CVD may help to develop 
novel, effective therapies useful in prevention and 
treatment of vascular disorders [8–12].
Type 2 diabetes mellitus (DM) is an independent 
CVD risk factor. Poorly controlled diabetes leads to the 
development of angiopathy. Detrimental effect of DM 
on vasculature is additionally amplified by concomitant 
disorders i.e. dyslipidaemia or hypertension. In diabetes 
CVD develops earlier than in non-diabetes population. 
Moreover, CVD in diabetes may be clinically silent, thus 
contributing to increased mortality risk seen in this group 
of patients. Proper CVD risk assessment in patients with 
diabetes is therefore of major importance [1–3].
People with diabetes share genetic risk factors with 
general population, however the total effect of meta-
bolic and hereditary mechanisms in this group can be 
different than in non-diabetes cohorts. The first GWA 
study revealed possible pathophysiological association 
of CVD and DM, since various polymorphisms in 9p21 
region were associated both with CAD and diabetes 
risk [4, 5]. Results of the subsequent studies, analysing 
the relationship between genome and clinical features 
of CAD in DM were often contradictory, which was to 
be expected due to heterogeneity of cohorts, mixed 
genetic background, methodological limitations and 
different multivariate statistical models used [17, 18]. 
Recently, new, highly specific for DM genetic CVD 
risk factor was identified. The polymorphism in re-
gion 1q25 is associated with increased risk of CAD in 
diabetic patients, and not in people without diabetes. 
1q25 genetic variants influence the glutamic pathway 
through the regulation of expression of glutamate-
ammonia ligase, encoding by GLUL gene located in 
1q25 region [19, 20].
The aim of our study was to examine the effects of 
two already known CVD-associated genome regions: 
9p21 and 1q25 on early incidence and clinical course of 
CAD in diabetic patients. These regions were selected 
because they have been previously demonstrated as 
important risk factors for development of premature 
CAD in general population as well as in diabetic pa-
tients. Additionally, some previous studies suggested 
strong correlation of genetic-dependent CAD risk with 
inaccurate metabolic control of diabetes and with other 
metabolic abnormalities. Therefore in our analysis we 
have been especially focused on possible cumulative 
effect of poor glycaemic control and/or existence of 
other metabolic risk factors on final effect of genetic 
polymorphisms.
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Material and methods
Inclusion criteria and patient’s selection
This case-control study was designed as a retro-
spective analysis and included 338 patients suffering 
from type 2 DM (T2DM) and CAD. CAD was defined as 
a history of acute myocardial infarction, coronary artery 
stent implantation or stenosis greater than 50% in one 
of the major coronary artery confirmed by coronarogra-
phy (240 patients) or CAD diagnosis in medical records 
with corresponding ECG findings (98 patients). Subjects 
were recruited from database of the diabetes and 
cardiology centers of the Medical University of Lodz, 
(Lodz, Poland). All subjects were Polish Caucasians, in-
habitants of Central Poland. Patients with type 1, type 3 
and gestational diabetes, with pre-diabetes states, and 
patient with coronary artery disease reported but not 
confirmed were excluded from the study.
Study procedures
The study protocol was approved by the Eth-
ics Committee of Medical University of Lodz and all 
subjects gave written consent prior to participation. 
Physical examination, was conducted in all patients, 
fasting blood samples were obtained for laboratory 
analysis. Data on past medical and family history, health 
behaviours and habits (smoking, alcohol use), use of 
medications, serum lipids and HbA1c levels (measured 
up to 6 months prior to examination) were taken ret-
rospectively from patients records. Characteristic of the 
study cohort is given in Tables 1–3.
Genetic analysis
Genomic DNA was extracted from granulocytes 
and lymphocytes from peripheral whole blood samples 
using Kit AxyPrepMiniprep (AXYGEN) according to the 
standard protocol.
The 9p21-rs2383206, rs1333049, 1q25-rs10911021 
polymorphisms were genotyped using the TaqMan pre-
designed SNP genotyping assay (Applied Biosystems). 
According to the control of quality each 96-cell plate 
has a 6 random duplicates.
Statistical analysis
The results for continuous variables were presented 
as arithmetical means with standard deviations (± SD) 
or proportions. Distribution for continuous variables 
was calculated using Shapiro-Wilk’s test to assess 
their normality. Statistical significance was analysed 
using Student’s t-test (for normal distribution) or by 
U-Mann-Whitney test (for not-normal distribution). 
Categorical variables were assessed using c2 test. 
Hardy-Wienberg’s equilibrium and distribution of the 
genotypes between both subgroups were examined 
using c2 test. The association between each genotype 
and early occurrence of CAD was examined using lo-
gistic analysis and calculated as odds ratio (OR) with 
95% confidence intervals (CI). We created a recessive 
and dominant model for not-adjusted and adjusted 
OR for all SNPs. Statistical analysis was done by EXCEL 
for Windows ver. XP. Statistical significance was set 
at p < 0.05.
Results
Cohort
338 patients with diabetes and coronary artery 
disease were included onto the study. Total cohort has 
been divided into two groups: the study group with an 
early diagnosis of CAD made at the age < 65 years for 
Table 1. Epidemiological and clinical characteristic of the study cohort. The study group has been defined based on “early 
onset” of CAD; before 65 years for females and 55 years for males. The control group includes subjects with “late onset” 
of CAD (CAD diagnosed at age ≥ 65 years for females and ≥ 55 for males)
Study group (n = 180) Control group (n = 158) P value
Female/male ratio (%) 51.1 31.0 < 0.005
Mean age in years (± SD) 68.3 ± 9.3 74 ±8.9
Mean age of CAD diagnosis (± SD) 51.2 ± 81 65.2 ± 6.96 < 0.00001
Incidence of MI (%) 74.7 68.4 0.2314
Mean age of first MI (± SD) 55.8 ± 11.3 65.7 ± 8.8 < 0.00001
Incidence of AH (%) 93.3 92.9 0.8876
Mean age of AH diagnosis (± SD) 49.5 ± 8.5 56.2 ± 9.6 < 0.00001
Mean age of DM diagnosis (± SD) 53.9 ± 9.5 60.6 ± 9.9 < 0.00001
Mean duration of DM (± SD) 13.9 ± 9.8 13.2 ± 8.9 0.597
Stroke incidence (%) 19.2 15.2 0.3686
Smoking history ever (%) 69.9 70.8 0.8831
CAD — coronary artery disease; SD — standard deviation; MI — myocardial infarction; AH — arterial hypertension; DM — diabetes mellitus
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females and < 55 years for males (n = 180) and the 
control group with CAD diagnosed after 65 years for 
females and 55 for males (n = 158). As expected, mean 
age of CAD diagnosis was lower in the study group 
(51.2 ± 8.1 yrs.) than in the controls (65.2 ± 6.95 yrs.; 
p < 0.05). There were significantly more women in the 
study group than in the controls (51 vs. 31%; p < 0.05). 
The incidence of myocardial infarction (MI) was similar 
in both groups (74.7% vs. 68.4%, p = 0.1862) but the 
mean age of first MI was lower in the group with earlier 
CAD onset (55.8 ± 11.3 vs. 65.7 ± 8.8, p = 0.00001). 
However, we found that MI was more often the first 
clinical symptom of heart disease in the control group 
than in the study group. Hypertension was universally 
present in both groups (93.3% vs. 92.9%), however 
age at which it was diagnosed was lower in the study 
group (49.6 ± 8.5 vs. 56 ± 9.8, p < 0.00001). Subjects 
in the study group have been also statistically earlier 
diagnosed with diabetes (53.9 ± 9.5 vs. 60.6 ± 9.93 
yrs.; p < 0.00001) compared with the control group, 
however mean diabetes duration, treatment and num-
bers of insulin injections were comparable between 
both groups. There was also no difference in history of 
smoking (69.9% vs. 70.8%) and stroke incidence (19.2% 
vs. 15.5%; p = 0.36). Mean body weight, and waist 
circumference were almost the same in both groups. 
Slight but statistically significant difference in BMI was 
found (31.2 ± 4.5 in the study group vs. 29.9 ± 4.7 cm 
in the control group; p = 0.006), however there was 
no statistical difference in the prevalence of obesity 
(BMI > 30) between both groups (32.2 vs. 30.5%, 
p value £ 0.7389). There were also no significant dif-
ferences in blood lipid nor HbA1c levels. Odds ratio (OR) 
of early CAD development calculated for the single risk 
factor is shown in Table 3. Incidence of family history 
of CAD (70.0% in the study group vs 45.6%; in the 
control group; p < 0.00001), obesity (61.2% vs. 49.0%; 
p < 0.0297), diabetes (51.5% vs. 28.4%, p < 0.0023) 
and hypertension (77.1% vs. 47.8%; p < 0.00001) were 
statistically different in both groups what is presented 
in Table 4.
Analysis of polymorphisms in 9p21  
and 1q24 regions
In our study cohort Allele frequencies of CAD-asso-
ciated SNPs in 9p21 region (rs2383206 and rs1333049) 
and 1q25 region (rs10911021) were found to be in 
Hardy-Weinberg equilibrium. 
For both SNP’s in 9p21region, there were sig-
nificant differences in allele and genotype frequencies 
Table 2. Metabolic and biochemical features of study/control group
Study group Control group P value
Mean weight [kg ± SD] 86.8 ± 15.1 85.1 ± 15.8 0.401
Mean height [cm ± SD] 166.6 ± 8.7 168.4 ± 8.4 0.07
Mean BMI [kg/m2 ± SD] 31.2 ±4.5 29.9 ± 4.7 0.006
BMI < 30 (%) 44.8 55.0 0.0682
BMI ≥ 30 < 35 (%) 32.2 30.5 0.7389
BMI ≥ 35 (%) 23.0 14.6 0.054
Waist [cm ± SD] 108.5 ± 10.1 106.5 ± 13.5 0.201
Waist ≥ 80 cm F, ≥ 94 cm M (%) 95.1 88.9 0.08
Total cholesterol [mmol/L ± SD] 4.4 ± 1.33 4.5 ± 1.2 0,395
LDL-cholesterol [mmol/L ± SD] 2.4 ± 1.05 2.4 ± 1.07 0.942
HDL-cholesterol [mmol/L ± SD] 1.3 ± 0.56 1.4 ± 0.55 0.1311
Triglycerides [mmol/L ± SD] 2.3 ± 1.74 2.0 ± 1.25 0.116
HbA1c (% ± SD) 7.9 ± 0.17 (n = 113) 7.8 ± 0.19 (n = 98) 0.595
BMI — body mass index; SD — standard deviation; LDL — low-density lipoprotein; HDL — high-density lipoprotein; HbA1c — glycated hemoglobin
Table 3. Relative risk of early CAD development associated 
with conventional risk factors in our study cohort
OR
History of smoking 1.045
Actual smoking 0.93
BMI < 30 0.7
BMI 30–35 1.08
BMI > 35 1.75
Insulin therapy 1.24
Presence of hypertension 1.06
HbA1c ≥ 7% 1.11
LDL-cholesterol > 1.9 mmol/L 1.03
Sex (M/F) 2.3
BMI — body mass index; HbA1c — glycated hemoglobin; LDL — low-
-density lipoprotein
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between the study and control group. For rs2383206 
locus (Table 5), previously determined risk allele G was 
present in 62.4% of subjects with an early onset of CAD, 
comparing to 44% in the control group (p < 0.00001). 
G/G genotype associated with risk of CAD was present 
in 39.4% in study group comparing to 18.8% in the 
control one (p = 0.0001). For study purpose, based 
on previous publications, we used a recessive model 
of analysis for the SNP (GG vs. AA + AG), and such 
a difference in genotype frequencies between groups 
was equivalent with increased risk of early CAD in GG 
homozygotes (OR 2.81, 95% CI: 2.39–3.24). In multi-
variant multivariate analysis of our data, after statisti-
cal adjustment for all conventional risk factors of CVD 
(gender, obesity, smoking and hypertension history, 
lipid levels, glycaemic control) only slightly reduced OR 
for SNP rs2383206 (from 2.81 to 2.58).
For another SNP from 9p21 region, rs1333049, sim-
ilar difference in allele frequency was found (Table 6), 
although the analysis was done in a smaller number of 
subjects (n = 276). Allele C, previously demonstrated 
as associated with CAD risk, was more frequent in 
study group comparing to the control one (56.3% vs. 
43.4%, p = 0.0036). CC homozygote frequency under 
recessive model among the patient with early CAD was 
31.6% and 17.4% in control individuals (p = 0.0083). 
In logistic regression analysis the risk for early onset of 
CAD for subjects with CC genotype was significantly 
higher (OR 2.2, 95% CI: 1.83–2.91, adjusted OR 1.96).
The genetic analysis of polymorphism in 1q25 
locus: rs10911021 (related to glutamic pathway) did 
not reveal any significant difference in the alleles and 
genotypes frequencies between the control and study 
group in our cohort (data not published).
Relationship of 9p21 genotype  
and clinical phenotype
Poor glycaemic control strongly altered the 9p21-
-related risk of early CAD in diabetic patients (Figure 1). 
The percentage of patients with HbA1c > 7% and risk 
genotype G/G is 41.3% in patients with early CAD and 
only 15.9% in the control group (p = 0.0011). However, 
there was no statistical difference between the GG fre-
quency in the control and study group among patients 
with low HbA1c < 7% (31.6% vs. 22.9, p = 0.4039). OR 
for early CAD risk in GG homozygotes with HbA1c > 7% 
was 3.73, whereas total OR (evaluated independently of 
HbA1c levels) was 2.81 (Table 6). Among the subjects with 
HbA1c < 7% — OR for early CAD associated with risk 
Table 4. Role of hereditary predisposition to CAD and 
CAD-related diseases in early development of CAD in dia-
betic patients. Family history is considered as positive if 






Family history of CAD (%) 70.0 45.6 < 0.00001
Family history of obesity (%) 61.2 49.0 0.0297
Family history of DM (%) 51.5 28.4 0.0023
Family history  
of hypertension (%)
77.1 47.8 < 0.00001
CAD — coronary artery disease; DM — diabetes mellitus
Table 5. The genotype distribution and alleles frequencies for rs2383206 with evaluated OR for development of early 
CAD among carriers of the risk allele. OR for recessive model (GG vs. AA + AG)
rs2383206 Study group (n = 170) 
(%)
Control group (n = 149) 
(%)
P value OR 95% CI OR adjusted*
A/A 14.7% 30.9% 0.0005 0.4
A/G 45.9% 50.3% 0.4270 0.8
G/G 39.4% 18.8% 0.0001 2.8 2.39–3.24 2.57
*Adjusted by: sex (F/M),HA (Y/N), total chol < 4.5, LDL-chol > 1.9, HDL-chol < 1.0, TGL ≥ 1.7, BMI ≥ 35/< 35, smoking now (Y/N), HBA1c (≥ 7%)
Table 6. The genotype distribution and alleles frequencies for rs1333049 with evaluated OR for development of early 
CAD among carriers of the risk allele. OR for recessive model (CC vs. GG + CG)
rs1333049 Study group (n = 136) 
(%)
Control group (n = 121) 
(%)
P value OR 95% CI OR adjusted*
G/G 19.1% 30.6% 0.54
C/G 49.3% 52.1% 0.89
C/C 31.6% 17.4% 0.0083 2.2 1.83–2.58 1.97
*Adjusted by: sex (F/M), HA (Y/N), total chol < 4.5, LDL-chol > 1.9, HDL-chol < 1.0, TGL ≥ 1.7, BMI ≥ 35/< 35, smoking now (Y/N), HBA1c (≥ 7%)
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genotype was reduced to 1.56. Moreover, although the 
G/G phenotype was still more frequent in patients with 
early CAD and good glycaemic control (31.6%) compar-
ing to subjects with late CAD and good glycaemic control 
(HbA1c < 7%) (22.9%), this difference did not achieve 
the statistical significance (p = 0.403). Interestingly, 
the patients with BMI ≥ 30 and genotype G/G in locus 
rs2383206 had relatively lower risk of development of 
early CAD (OR 1.57) in logistic regression analysis than 
non-obese subjects (OR 2.96) (Figure 2).
Discussion
The role of genetic polymorphisms in pathogenesis 
of CVD is highlighted since the results of first GWAS 
were published [4, 5]. In this study we have focused 
on 3 previously described regions of human genome 
associated with increased risk of CAD in general and 
diabetic population: 9p21 and 1q25 [16, 19, 21, 22] 
searching for the correlation of those polymorphisms 
with early onset of coronary disease in diabetic patients.
The role of 9p21 region in the pathogenesis of 
CVD was established in 2007 [4, 5] and confirmed in 
high number of genetic studies both in general and 
clinically-selected populations (e.g. in DM or rheuma-
toid arthritis) [6, 7, 23]. In present study we demon-
strated that two previously known polymorphisms in 
9p21 region (rs2383206 and rs1333049) are important 
for development of early ischaemic heart disease in 
younger patient with DM. Carriers of risk alleles for 
both SNPs have consistently higher risk of early CAD, 
estimated in logistic regression analysis. OR over 2.5 
associated with rs2383206 locus and 2.0 for rs1333049, 
after adjustment for all known classic risk factors in 
logistic regression model, suggest a strong correlation 
of 9p21 loci with early CAD onset. Our observations 
confirm the data previously published by Doria et al. 
on the role of 9p21 SNPs in CAD development in DM 
[24]. It is also consistent with previous publications 
on the role of 9p21 region in progression of lesions 
in the coronary arteries, since the patients with risk 
alleles develop symptoms of CAD earlier than non- 
-carriers [25, 26]. There are contradictory reports about 
the increased risk of MI among 9p21 carriers — some 
authors like Zhang [27] Saleheen [28], Abdullah [25] 
have found an association with premature MI. In our 
study we didn’t see a significantly higher incidence 
of MI among patients with early CAD incidence. This 
observation is consistent with other author’s findings 
[29, 30, 32, 33], that didn’t find connection with early 
MI and 9p21 polymorphisms. Differences in the cor-
relation between the risk genotype and MI incidence 
found in the particular studies might suggest, that two 
separated haploblocks co-exist in 9p21 region: “pro-
atherogenic one” (including rs2383206, rs1333049) 
connected with CAD occurrence and another “pro-
thrombotic” — associated with MI risk [37]. Nonethe-
less, possible correlation between genotype and MI 
incidence could have potential influence on results of 
our retrospective study by “survival effect”, since MI 
is the most serious consequence of CAD, associated 
with high mortality. In our study mean age of a first MI 
was lower in early group, and the difference reached 
statistical significance (55.8 ± 11.3 vs. 65.7 ± 8.8, 
p < 0.0001); however, the incidence between both 
groups was comparable. Potential mortality of MI is 
associated with many additional factors, like patient’s 
general condition or age, but also with extensity of 
MI. In our opinion, younger patients with more rapid 
progression of atherosclerotic plaque (due to genetic 
predisposition) and with potentially lower chance for 
developing efficient collateral circulation, could have 
higher risk of sudden death during the first episode of 
MI. So, “survival effect” is rather not expected between 
Figure 2. The risk of development early CAD in GG carriers 
rs23803206 with association of BMI < 30 kg/m2 and ≥ 30 kg/m2)
Figure 1. The risk of development early CAD in GG carriers 
rs23803206 with association of poor glycaemic control 
(HbA1c ≥ 7%)
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the carriers of risk alleles, but, further prospective stud-
ies should be conducted to confirm our hypothesis.
Precise mechanisms of action of 9p21 region 
SNPs in CAD is not clear, since a major risk allele in 
this region is located in anti-sense non-coding RNA 
INK4 locus (called ANRIL) [34]. This genome area could 
potentially have regulatory function on expression of 
cyclin-dependent kinase inhibitors encoded by CDKN2A 
and CDKN2B genes and controlling the cell cycle and 
cellular proliferation [35]. The inhibitory effect of 9p21 
on kinase inhibitors coded on chromosome 9 may 
be also indirectly associated with interferon-gamma/ 
/STAT1 pathway (since the risk allele in 9p21 region is in 
linkage disequilibrium with two SNPs existing in bind-
ing site for transcription factor STAT1). Nevertheless, 
9p21-associated susceptibility to CVD is independent 
of other risk factors, like hypertension or cholesterol 
level. Therefore, the 9p21 region seems to be a good 
candidate for a novel therapeutic option in coronary 
artery disease or stroke, especially regarding high in-
cidence of risk allele in Caucasian (~75%) and Asian 
population [36]. OR for GG homozygotes (rs2383206) 
is the highest among all analysed risk factors (Table 3). 
Also statistical adjustment by known risk factors in 
logistic regression model does not change OR evalu-
ated for particular SNPs from 9p21 region, what sug-
gest independent, unique mechanism of 9p21 loci in 
expression of premature CAD.
Still, we have also identified some metabolic condi-
tions that can affect the 9p21-associated risk of early 
CAD. Disadvantageous biological effect of rs2383206 
on the onset of CAD can be strongly upregulated in 
patients with poor glycaemic control (Figure 1). These 
findings are parallel with previous observations of Doria 
et al. on the role of genetic and metabolic conditions in 
pathogenesis of CAD during DM [24]. Additionally, we 
have found that negative effect of 9p21 polymorphism 
on early onset of CAD in diabetic patients is particu-
larly pronounced in the patients without obesity (BMI 
< 30 kg/m2). Since obesity is the risk factor of both 
DM and CAD (also in our cohort OR 1.57), it is striking 
that patients with optimal or sub-optimal weight con-
trol may be more susceptible to early CAD (Figure 2). 
It demonstrates that obesity and 9p21-mediated pre-
disposition of CAD are independent risk factors for 
atherosclerosis in coronary arteries and suggests that 
the disadvantage of carriage of both risk alleles in 9p21 
locus is more obvious in non-obese patients. Moreover, 
it may suggests that genetic risk factors are more im-
portant than metabolic ones and they should be taken 
under consideration as a part of a risk score scales.
Besides of 9p21 region, we have also analysed 
other polymorphism on chromosome 1 associated with 
CAD risk — rs10911021 [19, 37]. We have not found 
any association of polymorphism in locus rs10911021 
in 1q25 region with risk of premature CAD. Activity 
of GLUL gene (regulator of expression of glutamate-
ammonia ligase) located in 1q25 region is particularly 
and selectively related to risk of CAD in DM [19, 20]. 
So, rs10911021 seemed to be a good candidate for our 
study. However, we were unable to find any difference 
in allele and genotype frequencies between study and 
control groups. It could be simply explained by the 
fact that all patients contributing to our study have 
DM and 1q25-mediated predisposition to CAD may 
depend on polymorphism in this region in binary way. 
So, the phenotype associated with SNP rs10911021 
might determine incidence of CAD but not the time 
of its onset.
The strength of the study is the stringent criteria 
used for the sample selection for the study — polish 
diabetic population with CAD and the p value for the 
association. Genotyping method with TaqMan prede-
signed primers is reliable, and duplicates confirmed 
accuracy of results. However, our study has clear limita-
tions, like the relative small sample size (that enables an 
identification of more specific sub-groups and further 
genetic analysis of identified cohorts) or difference in 
sex distribution (that in our opinion may be ignored, 
since the criteria of recruitment to clinical groups are 
different for both genders). Also retrospective character 
of our study, must be provided for analysis of our find-
ings. As we mentioned, the “survival effect” is rather 
not expected in context of obtained results. However 
other limitations specific for retrospective studies, like 
continuous changes of medical standards for diagnosis 
and management of both diseases as well as improving 
outcome after early treatment of DM and CAD during 
last decade, may potentially affect the results and 
should be considered during interpretation of data. 
In summary, we confirmed a role of 9p21 region 
as an important risk factor of CAD in diabetic patients. 
A strong association of SNPs frequencies (GG for 
rs2383206 and CC for rs1333049) with risk of early CAD 
onset was found. Genetic predisposition associated 
with 9p21 region is independent of any other known 
risk factor evaluated in our patients. Moreover, the 
effect of 9p21 is amplified by poor glycaemic control 
(HbA1c > 7%) and seems to be especially prominent in 
patients with relatively normal or only slightly elevated 
BMI (< 30 kg/m2). All in all, since polymorphisms are 
stable/constant during lifetime, genotyping them could 
distinguish a group of patients who are especially 
recommended for preventive treatment and modifica-
tion of lifestyle. Since hereditary susceptibility to CVD 
is known already for a while, adding even the single, 
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14 www.dk.viamedica.pl
well-characterized polymorphism to CAD-risk scale can 
significantly improve its power and accuracy.
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